ChemoCentryx announces avacopan presentations at ASN
ChemoCentryx announced presentations of its lead drug candidates avacopan, a complement 5a receptor inhibitor, and CCX140, an inhibitor of the chemokine receptor known as CCR2, during the American Society of Nephrology, ASN, Kidney Week 2018, the world's premier nephrology meeting, being held October 23-28 in San Diego. Primary endpoints of the Phase III ADVOCATE trial are proportion of patients in remission at week 26 based on a Birmingham Vasculitis Activity Score of zero and not taking glucocorticoid steroids within 4 weeks prior to week 26 and proportion of patients who sustain remission from week 26 through week 52 and not taking GCS within 4 weeks prior to week 52. Quality of life will also be assessed over the 52 weeks. Other endpoints include adverse events, requirement for rescue medications, renal disease markers, GCS Toxicity Index, and Vasculitis Damage Index.ChemoCentryx recently announced the completion of patient enrollment in the ADVOCATE Phase III pivotal trial with 316 patients enrolled with topline data expected in Q4 2019.